RxDoctor Payments Data

Satish Bhutani, MD

Internal Medicine · Toms River, NJNPI 1013995893

Payments from drug & device makers

$3,056in general payments, 2019–2025

Across 202 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$558
  • AstraZeneca$465
  • Lilly USA, LLC$444
  • Novo Nordisk$328
  • Amarin Pharma, Inc.$248
  • Merck$181
  • plus $832 from 16 others

What the payments were for

  • Food & beverage$3,056100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,056 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$119,398
Medicare patients
355
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$133,161
FarxigaDapagliflozin Propanediol87$99,451
JanuviaSitagliptin Phosphate48$72,244
EliquisApixaban70$59,494
JardianceEmpagliflozin43$44,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$44,856
TrulicityDulaglutide18$28,133
XareltoRivaroxaban28$27,125
Icosapent Ethyl54$23,089
VascepaIcosapent Ethyl33$13,816
TradjentaLinagliptin19$12,879
Combivent RespimatIpratropium/Albuterol Sulfate11$11,386
SynthroidLevothyroxine Sodium85$7,145
Rosuvastatin Calcium448$6,233
SteglatroErtugliflozin Pidolate12$6,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$328$133,16180 claims
AstraZenecaFarxiga$465$99,45187 claims
MerckJanuvia, Steglatro$181$78,38660 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$88$69,23973 claims
PfizerEliquis$156$59,49470 claims
GSKTrelegy Ellipta$558$44,85645 claims
Lilly USA, LLCTrulicity$444$28,13318 claims
Johnson & JohnsonXarelto$13$27,12528 claims
AbbVieSynthroid$96$7,14585 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →